Salbutamol

English name albuterol

also known as albuterol · albuterol Sulfate · Ventolin · Salbutamol Sulfate · PROAIR HFA · salbutamol sulphate · Albuterol Spiromax · A006 · +46 more

Developed for: asthma · chronic obstructive pulmonary disease · exercise-induced bronchoconstriction · bronchiolitis · childhood onset asthma · acute asthma · cystic fibrosis · obstructive lung disease
+44 more
· lung disorder · respiratory syncytial virus bronchiolitis · status asthmaticus · acute bronchiolitis · acute lung injury · acute respiratory failure · amyotrophic lateral sclerosis · bronchial disorder · bronchitis · bronchopulmonary dysplasia · congenital myasthenic syndrome · congestive heart failure · facioscapulohumeral muscular dystrophy · food allergy · generalized myasthenia gravis · glycogen storage disease due to acid maltase deficiency, infantile onset · glycogen storage disease due to acid maltase deficiency, late-onset · glycogen storage disease II · isoproterenol-mediated vasodilatation · left ventricular failure · lymphangioleiomyomatosis · mucus inspissation of respiratory tract · multiple sclerosis · muscular dystrophy, scapulohumeral · organophosphate poisoning · persistent tachypnoe of infancy, usual · pulmonary arterial hypertension · pulmonary edema · pulmonary hypertension · respiratory failure · spinal cord injury · upper limb hypertrophy · urinary tract obstruction · ventricular septal defect · adult acute respiratory distress syndrome · allergic asthma · cardiomyopathy · congenital myopathy · heart failure · idiopathic pulmonary arterial hypertension · myopathy · pulmonary hypertension, neonatal · reactive airway disease · Riley-Day syndrome
Investigated by: Teva Branded Pharmaceutical Products R&D, Inc. · AstraZeneca · Boehringer Ingelheim · GlaxoSmithKline · Amphastar Pharmaceuticals, Inc. · National Heart, Lung, and Blood Institute (NHLBI)
+149 more
· Assistance Publique - Hôpitaux de Paris · Duke University · Hadassah Medical Organization · Parexel · Sumitomo Pharma America, Inc. · University of California, San Francisco · University of Copenhagen · Aerogen · Assiut University · Bond Avillion 2 Development LP · Chiesi Farmaceutici S.p.A. · Concentrx Pharmaceuticals, Inc. · Fraunhofer-Institute of Toxicology and Experimental Medicine · Henan University of Traditional Chinese Medicine · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · Kramer Consulting, LLC · Laval University · Mayo Clinic · Mylan Pharmaceuticals Inc · Nemours Children's Clinic · Ohio State University · Pennington Biomedical Research Center · PharPoint Research, Inc. · Rambam Health Care Campus · Taiwan Otsuka Pharm. Co., Ltd · University Hospital, Tours · University of Aarhus · University of Arizona · University of British Columbia · University of Miami · Vanderbilt University Medical Center · Acerus Pharmaceuticals Corporation · American College of Clinical Pharmacy · Armed Forces Hospital, Pakistan · Australian Lung Health Initiative Pty Ltd · Autoimmunity Centers of Excellence · Beijing Chao Yang Hospital · Bispebjerg Hospital · California Transplant Donor Network · Cambridge University Hospitals NHS Foundation Trust · Caring Friends, Mumbai · Central Hospital, Nancy, France · Chang Gung Memorial Hospital · Chang Gung University · Children's Hospital Los Angeles · Chongqing Medical University · Cipla Ltd. · Clinical Trial Unit, University Hospital Basel, Switzerland · Clínica Vespucio, Santiago, Chile · Conselho Nacional de Desenvolvimento Científico e Tecnológico · Dey · Dr. J. Alberto Neder · ETH Zurich (Switzerland) · Eli Lilly and Company · Erasmus Medical Center · FDA Office of Orphan Products Development · Federal University of Rio Grande do Norte · First Affiliated Hospital Xi'an Jiaotong University · First Affiliated Hospital of Chongqing Medical University · Flight Attendant Medical Research Institute · Fortrea · Guangzhou Panyu Central Hospital · Hamilton Health Sciences Corporation · Helsinki University Central Hospital · Hospital Infantil de Mexico Federico Gomez · IRCCS Azienda Ospedaliero-Universitaria di Bologna · Ibirapuera University · Imperial College London · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Intech Biopharm Ltd. · Johns Hopkins University · Jordan University of Science and Technology · Kern Medical Center · Khyber Teaching Hospital · all 155 on the full record

Regulatory milestones approvals, filings & regulatory actions · 14 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	PROAIR RESPICLICK	—	2016-04-28	fda.gov ↗
Label expansions (2)	US (FDA)	PROAIR HFA	—	2006-02-03 – 2008-09-16	fda.gov ↗
Label expansion	US (FDA)	VENTOLIN HFA	—	2008-03-26	fda.gov ↗
Label expansions (2)	US (FDA)	PROVENTIL-HFA	—	1998-09-23 – 1999-06-02	fda.gov ↗
Label expansion	US (FDA)	VOLMAX	—	1997-10-08	fda.gov ↗
Label expansions (3)	US (FDA)	PROVENTIL	—	1984-09-13 – 1997-09-18	fda.gov ↗
Label expansions (3)	US (FDA)	VENTOLIN	—	1990-09-24 – 1997-06-16	fda.gov ↗
Approved	US (FDA)	VENTOLIN	—	1981-05-01	fda.gov ↗

Trials 199 · started per year

today

US approved 1981

1980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 05 trials
Phase 0	NCT07591558	Jun → Oct 2026 expected	diabetes mellitus, lung disorder	King Abdullah University Hospital	Not yet recruiting	No outcome recorded
Phase 0	NCT06319183	Mar → Jun 2024	—	Tongji University	Unknown	No outcome recorded
Phase 0	NCT06139029	Nov 2022 → Mar 2023	acute bronchiolitis	Mardan Medical Complex	Completed	No outcome recorded
Phase 0	NCT03889379	Jan 2019 → Jun 2021	—	University of Arizona	Withdrawn	No outcome recorded
Phase 0	NCT02135965	Apr 2009 → Aug 2011	—	Pennington Biomedical Research Center	Completed	No outcome recorded
Phase 129 trials
Phase 1	NCT06514157	Aug → Sep 2024	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT06433921	Aug 2024 → Feb 2027 expected	asthma	GlaxoSmithKline	Recruiting	No outcome recorded
Phase 1	NCT06921291	Aug → Dec 2024	—	Khyber Teaching Hospital	Completed	No outcome recorded
Phase 1	NCT06433908	Jun → Oct 2024	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT06290102	May → Oct 2024	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 1	NCT06271408	Feb → Apr 2024	chronic obstructive pulmonary disease	Polarean, Inc.	Unknown	No outcome recorded
Phase 1	NCT06027606	Sep 2023 → Sep 2025	—	University of Alberta	Completed	No outcome recorded
Phase 1	NCT05791565	Apr → May 2023	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT03436225	Feb 2019	respiratory syncytial virus bronchiolitis	Assiut University	Unknown	No outcome recorded
Phase 1	NCT03772223	Jan → May 2019	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT03514615	Jan → Jul 2018	—	University Hospitals, Leicester	Completed	No outcome recorded
Phase 1	NCT03373409	Nov 2017 → May 2018	asthma	Concentrx Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT03098680	Apr 2017 → Feb 2020	cardiovascular disorder	Cambridge University Hospitals NHS Foundation Trust	Terminated	No outcome recorded
Phase 1	NCT03480997	Dec 2016 → Apr 2017	chronic obstructive pulmonary disease	Pneuma Respiratory, Inc	Completed	No outcome recorded
Phase 1	NCT02566252	Jul 2015 → Jan 2016	—	Pulmotect, Inc.	Completed	No outcome recorded
Phase 1	NCT01984086	Oct 2013 → May 2014	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01895998	Aug 2013 → Apr 2014	sickle cell disease	Duke University	Completed	No outcome recorded
Phase 1	NCT01844401	Apr → Aug 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 1	NCT01859624	Jun 2012 → Apr 2013	glycogen storage disease due to acid maltase deficiency, late-onset	Duke University	Completed	No outcome recorded
Phase 1	NCT01457261	Apr 2012 → Nov 2014	idiopathic pulmonary fibrosis	Royal Brompton & Harefield NHS Foundation Trust	Completed	No outcome recorded
Phase 1	NCT01263197	Dec 2010 → Mar 2011	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT01203592	Sep 2010 → Aug 2013	congenital myasthenic syndrome	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT02207452	Aug 2010 → Jul 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01056159	Jan → Jun 2010	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 1	NCT00674050	May → Sep 2008	diabetes mellitus	Mannkind Corporation	Completed	No outcome recorded
Phase 1	NCT00549120	Aug → Oct 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00649987	Sep → Oct 2005	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00649779	Sep → Oct 2005	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT02173678	Oct → Nov 1999	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT01799538	Jun 2013 → Nov 2027 expected	lymphangioleiomyomatosis	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	No outcome recorded
Phase 1/2	NCT01885936	Jun 2013 → Dec 2016	glycogen storage disease II	Duke University	Completed	No outcome recorded
Phase 222 trials
Phase 2	NCT06644924	Feb → Jun 2025	asthma	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT05860244	Sep 2024 → Jul 2025	amyotrophic lateral sclerosis	Assistance Publique - Hôpitaux de Paris	Unknown	No outcome recorded
Phase 2	NCT03643874	Jun → Aug 2018	asthma	Concentrx Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT03371459	Dec 2017 → Mar 2018	asthma	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT03364608	Dec 2017 → Mar 2018	asthma	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT03270332	Oct 2017 → Jul 2020	pulmonary hypertension	University of Miami	Completed	No outcome recorded
Phase 2	NCT02542254	Oct → Dec 2015	chronic obstructive pulmonary disease	Verona Pharma, Inc.	Completed	No outcome recorded
Phase 2	NCT01957293	Oct 2013 → Jan 2014	—	University of Basel	Completed	No outcome recorded
Phase 2	NCT01252758	Nov 2012 → Apr 2013	asthma	Acerus Pharmaceuticals Corporation	Withdrawn	No outcome recorded
Phase 2	NCT01581177	Apr → Jul 2012	asthma	Amphastar Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT01958814	Feb 2012 → Jul 2015	respiratory failure	University Hospital, Tours	Completed	No outcome recorded
Phase 2	NCT01470755	Jan 2012 → Jan 2014	asthma	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT01189396	Jul → Dec 2010	asthma, chronic obstructive pulmonary disease	Amphastar Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT01174732	Jul → Oct 2010	asthma	Amphastar Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT01058863	Feb → Jun 2010	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 2	NCT00818454	Dec 2008 → Sep 2009	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00696540	Jun → Sep 2008	bronchiolitis	University Diego Portales	Unknown	No outcome recorded
Phase 2	NCT00310401	Apr 2007 → May 2011	pulmonary edema	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 2	NCT00358488	Apr 2006 → Jan 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00320034	Apr 2006 → Jun 2008	asthma	Hamilton Health Sciences Corporation	Completed	No outcome recorded
Phase 2	NCT00096616	Nov 2004 → Mar 2006	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02182674	Oct 2000 → Aug 2001	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 2/34 trials
Phase 2/3	NCT06815679	Mar 2025 → Jan 2026 overdue	acute respiratory failure, pneumonia	Università degli Studi di Ferrara	Not yet recruiting	No outcome recorded
Phase 2/3	NCT03914638	Apr 2019 → Oct 2021	generalized myasthenia gravis	University of Aarhus	Unknown	No outcome recorded
Phase 2/3	NCT01375361	Apr 2009 → Jul 2010	congestive heart failure	University of California, San Francisco	Withdrawn	No outcome recorded
Phase 2/3	NCT00755079	Apr 2007 → Aug 2012	spinal cord injury	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 348 trials
Phase 3	NCT06664619	Dec 2024 → Sep 2026 expected	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Recruiting	No outcome recorded
Phase 3	NCT06471257	Jun 2024 → Oct 2026 expected	asthma	AstraZeneca	Recruiting	No outcome recorded
Phase 3	NCT06307665	May 2024 → Oct 2027 expected	asthma	AstraZeneca	Recruiting	No outcome recorded
Phase 3	NCT06245551	Dec 2023 → Jun 2024	exercise-induced bronchoconstriction	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT06154304	Dec 2023 → Sep 2024	asthma	Cipla Ltd.	Completed	No outcome recorded
Phase 3	NCT05653024	Jul 2023 → May 2025	food allergy	Philippe Bégin	Terminated	No outcome recorded
Phase 3	NCT05505734	Sep 2022 → Aug 2024	asthma	Bond Avillion 2 Development LP	Completed	No outcome recorded
Phase 3	NCT06946264	Jul 2022 → Dec 2029 expected	bronchiolitis	Nemours Children's Clinic	Recruiting	No outcome recorded
Phase 3	NCT04234464	Jan → Aug 2020	exercise-induced bronchoconstriction	Bond Avillion 2 Development LP	Completed	No outcome recorded
Phase 3	NCT03449056	Jan 2019 → Jan 2020	chronic obstructive pulmonary disease	Poitiers University Hospital	Unknown	No outcome recorded
Phase 3	NCT03528577	Sep 2018 → Mar 2019	asthma	Sun Pharmaceutical Industries, Inc.	Completed	No outcome recorded
Phase 3	NCT03816267	May 2018 → Mar 2019	asthma	Suez Canal University	Completed	No outcome recorded
Phase 3	NCT03256695	Sep 2017 → Apr 2018	chronic obstructive pulmonary disease	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT03169504	May 2017 → May 2018	chronic obstructive pulmonary disease	Henan University of Traditional Chinese Medicine	Unknown	No outcome recorded
Phase 3	NCT02969408	Feb 2017 → Feb 2018	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT03208894	Nov 2016 → May 2017	persistent tachypnoe of infancy, usual	Armed Forces Hospital, Pakistan	Completed	No outcome recorded
Phase 3	NCT02885636	Sep 2016 → Sep 2017	left ventricular failure	Mayo Clinic	Completed	No outcome recorded
Phase 3	NCT02782052	Jul 2016 → Oct 2018	pulmonary arterial hypertension	Assistance Publique - Hôpitaux de Paris	Withdrawn	No outcome recorded
Phase 3	NCT02160548	Apr → Dec 2015	organophosphate poisoning	Sylhet M.A.G.Osmani Medical College	Completed	No outcome recorded
Phase 3	NCT02126839	May 2014 → Feb 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT01836016	May 2013 → May 2015	chronic obstructive pulmonary disease	Henan University of Traditional Chinese Medicine	Unknown	No outcome recorded
Phase 3	NCT01857323	May → Aug 2013	asthma, chronic obstructive pulmonary disease	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT01791972	Mar → May 2013	exercise-induced bronchoconstriction	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT01424813	Dec 2012 → Oct 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT01747629	Dec 2012 → Oct 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT01698320	Oct 2012 → Dec 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT01218009	Oct → Dec 2010	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Terminated	No outcome recorded
Phase 3	NCT01095016	Mar 2010 → Sep 2012	asthma	Taiwan Otsuka Pharm. Co., Ltd	Completed	No outcome recorded
Phase 3	NCT01096017	Mar → Apr 2010	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01076322	Mar 2009 → Jun 2010	asthma	Taiwan Otsuka Pharm. Co., Ltd	Completed	No outcome recorded
Phase 3	NCT00669617	Apr → Aug 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 3	NCT00634517	Mar → Dec 2008	asthma	Amphastar Pharmaceuticals, Inc.	Terminated	No outcome recorded
Phase 3	NCT00634829	Feb → Oct 2008	exercise-induced bronchoconstriction	Amphastar Pharmaceuticals, Inc.	Terminated	No outcome recorded
Phase 3	NCT00528723	Nov 2007 → Jan 2009	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT00635505	Sep 2007 → Aug 2008	asthma	Amphastar Pharmaceuticals, Inc.	Terminated	No outcome recorded
Phase 3	NCT00577655	Aug 2007 → Jul 2008	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT00990847	Jun 2007 → Apr 2008	acute asthma	PT Otsuka Indonesia	Completed	No outcome recorded
Phase 3	NCT00462540	May → Sep 2007	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 3	NCT00400153	Nov 2006 → Apr 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00308685	Jun → Dec 2006	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT00252863	Dec 2004 → May 2006	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00144846	Sep 2004 → Feb 2006	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00085774	Jun → Sep 2004	exercise-induced bronchoconstriction	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02177253	Oct 2002 → Mar 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00382889	Aug 2002 → Sep 2004	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT00665600	Feb 2002 → Mar 2003	chronic obstructive pulmonary disease	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 3	NCT02182700	Jul 1998 → Dec 1999	asthma	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 3	NCT00000577	Sep 1993 → Jul 2008	asthma, lung disorder	Milton S. Hershey Medical Center	Withdrawn	No outcome recorded

Phase 445 trials
Phase 4	NCT07426458	Apr 2026 → Apr 2028 expected	asthma	University of Miami	Recruiting	No outcome recorded
Phase 4	NCT07166939	Nov 2025 → Jun 2027 expected	acute asthma	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 4	NCT06825013	Nov 2024 → Jan 2027 expected	chronic obstructive pulmonary disease	Dr. J. Alberto Neder	Recruiting	No outcome recorded
Phase 4	NCT06563102	Sep 2024 → Feb 2026	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT06158893	Aug 2024 → Aug 2025	—	Assiut University	Unknown	No outcome recorded
Phase 4	NCT06422689	May 2024 → Feb 2027 expected	asthma	AstraZeneca	Active not recruiting	No outcome recorded
Phase 4	NCT04184609	Jul → Nov 2023	childhood onset asthma, obesity disorder	Ohio State University	Withdrawn	No outcome recorded
Phase 4	NCT05084222	Nov 2021 → Jun 2023	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 4	NCT05087693	Nov 2021 → Aug 2023	bronchial disorder	University of British Columbia	Completed	No outcome recorded
Phase 4	NCT04677959	Feb 2021 → Mar 2022	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 4	NCT04606394	Dec 2020 → Dec 2021	chronic obstructive pulmonary disease	Pulmonary Research Institute of Southeast Michigan	Completed	No outcome recorded
Phase 4	NCT03890666	Oct 2020 → Oct 2021	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 4	NCT04012138	Dec 2019 → Dec 2025	—	Nantes University Hospital	Completed	No outcome recorded
Phase 4	NCT04207840	Dec 2019	anaphylaxis, asthma	Amphastar Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 4	NCT03924635	Aug 2019 → Dec 2022	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT03586544	Sep 2018 → Mar 2020	childhood onset asthma, exercise-induced bronchoconstriction, obesity disorder	University of Nevada, Las Vegas	Terminated	No outcome recorded
Phase 4	NCT02966184	Sep → Oct 2018	status asthmaticus	Norton Healthcare	Terminated	No outcome recorded
Phase 4	NCT03493503	Apr 2017 → May 2019	status asthmaticus	Erasmus Medical Center	Completed	No outcome recorded
Phase 4	NCT02914652	Oct 2016 → Jul 2017	ventricular septal defect	University of Aarhus	Completed	No outcome recorded
Phase 4	NCT03044938	Aug 2016	asthma	Ibirapuera University	Completed	No outcome recorded
Phase 4	NCT02797275	Jun 2016 → Dec 2026 expected	obstructive lung disease	University of California, San Francisco	Active not recruiting	No outcome recorded
Phase 4	NCT03199976	Apr 2016 → Nov 2020	asthma, bronchitis, obstructive lung disease	Helsinki University Central Hospital	Terminated	No outcome recorded
Phase 4	NCT02447250	Oct 2013 → Dec 2014	bronchopulmonary dysplasia	Oregon Health and Science University	Completed	No outcome recorded
Phase 4	NCT02405598	Oct 2013 → Jul 2015	glycogen storage disease due to acid maltase deficiency, infantile onset	National Taiwan University Hospital	Completed	No outcome recorded
Phase 4	NCT01903785	May 2013 → Dec 2014	exercise-induced bronchoconstriction	University of British Columbia	Completed	No outcome recorded
Phase 4	NCT01721291	Oct 2012 → Nov 2017	asthma, chronic obstructive pulmonary disease	Imperial College London	Completed	No outcome recorded
Phase 4	NCT02103374	Jan 2012 → Dec 2015	chronic obstructive pulmonary disease	University Hospital, Tours	Completed	No outcome recorded
Phase 4	NCT01112241	Apr → May 2010	transplant-related bronchiolitis obliterans	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	Completed	No outcome recorded
Phase 4	NCT02877537	Oct 2008 → Apr 2012	asthma	Central Hospital, Nancy, France	Completed	No outcome recorded
Phase 4	NCT00783250	Sep 2008 → Aug 2011	chronic obstructive pulmonary disease	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Terminated	No outcome recorded
Phase 4	NCT00440245	Feb 2007 → Jul 2010	asthma, chronic obstructive pulmonary disease	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT00388882	Oct 2006 → Oct 2007	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00385359	Oct 2006 → ?	asthma	University Health Network, Toronto	Unknown	No outcome recorded
Phase 4	NCT00359788	Jul 2006 → Apr 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00354354	Mar 2006 → Jul 2009	chronic obstructive pulmonary disease	Queen's University	Completed	No outcome recorded
Phase 4	NCT00273689	Dec 2005 → Sep 2007	exercise-induced bronchoconstriction	University of New Mexico	Completed	No outcome recorded
Phase 4	NCT00325767	May 2004 → Sep 2005	mucus inspissation of respiratory tract	Johns Hopkins University	Completed	No outcome recorded
Phase 4	NCT00272753	Apr 2004 → Nov 2005	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT07436104	Jan 2004 → Dec 2015	asthma, chronic diarrheal disease, chronic obstructive pulmonary disease, hypertensive disorder +2	MAHAN Trust	Completed	No outcome recorded
Phase 4	NCT00273962	May 2002 → Nov 2003	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00361452	Dec 2000 → May 2001	respiratory syncytial virus bronchiolitis	Rambam Health Care Campus	Terminated	No outcome recorded
Phase 4	NCT02235428	Sep 1998	asthma	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 4	NCT02182713	May → Sep 1998	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02182856	Feb 1998 → Jul 2000	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00940927	Jul 1993 → Oct 1994	asthma	Nemours Children's Clinic	Completed	No outcome recorded

Phase not applicable44 trials
—	NCT07378605	Jan → Mar 2026 overdue	—	Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital	Not yet recruiting	No outcome recorded
—	NCT06426082	Nov 2024 → Aug 2025 overdue	cardiovascular-kidney-metabolic syndrome	Universidad de Almeria	Not yet recruiting	No outcome recorded
—	NCT06276231	Jul 2024 → Mar 2026	urinary tract obstruction	Oman Medical Speciality Board	Unknown	No outcome recorded
—	NCT06754631	Apr → Sep 2024	childhood onset asthma	Muhammad Aamir Latif	Completed	No outcome recorded
—	NCT05932316	May 2023 → Apr 2024	bronchiectasis, bronchiolitis, cystic fibrosis, immunodeficiency disease +1	Rambam Health Care Campus	Unknown	No outcome recorded
—	NCT05914285	Apr 2023 → Jun 2025 overdue	chronic obstructive pulmonary disease	Yonsei University	Active not recruiting	No outcome recorded
—	NCT05786950	Jan → Jul 2023	chronic obstructive pulmonary disease	The First Affiliated Hospital of Guangzhou Medical University	Completed	No outcome recorded
—	NCT05589441	Oct 2022 → Oct 2023	—	First Affiliated Hospital Xi'an Jiaotong University	Unknown	No outcome recorded
—	NCT04912596	Aug 2022 → Jan 2025 overdue	asthma	Intech Biopharm Ltd.	Recruiting	No outcome recorded
—	NCT04402658	Aug 2022 → May 2023	substance abuse	Norwegian School of Sport Sciences	Withdrawn	No outcome recorded
—	NCT05241288	Mar 2022 → Feb 2023	chronic obstructive pulmonary disease	University of North Carolina, Chapel Hill	Completed	No outcome recorded
—	NCT04914273	Jun → Aug 2021	—	Fraunhofer-Institute of Toxicology and Experimental Medicine	Completed	No outcome recorded
—	NCT04615611	Nov 2020 → Nov 2021	—	University of Copenhagen	Unknown	No outcome recorded
—	NCT04558190	Sep 2020 → Nov 2021	—	University of Copenhagen	Completed	No outcome recorded
—	NCT03524066	Apr → Dec 2018	—	Fraunhofer-Institute of Toxicology and Experimental Medicine	Completed	No outcome recorded
—	NCT03091504	Sep 2017 → Mar 2018	—	Rush University Medical Center	Completed	No outcome recorded
—	NCT03071731	Apr 2017 → Jun 2019	chronic obstructive pulmonary disease	Laval University	Unknown	No outcome recorded
—	NCT03271905	Apr 2017 → Dec 2018	asthma, chronic obstructive pulmonary disease	Federal University of Rio Grande do Norte	Unknown	No outcome recorded
—	NCT02925130	Oct 2016 → Sep 2017	—	University Hospital, Grenoble	Completed	No outcome recorded
—	NCT02818270	Jun → Dec 2016	chronic obstructive pulmonary disease	Chang Gung University	Completed	No outcome recorded
—	NCT02740660	Apr 2016 → Oct 2017	—	Pennington Biomedical Research Center	Completed	No outcome recorded
—	NCT02678949	Mar → Aug 2016	childhood onset asthma	Hospital Infantil de Mexico Federico Gomez	Unknown	No outcome recorded
—	NCT02802111	Jun 2015 → Sep 2017	—	Children's Hospital Los Angeles	Completed	No outcome recorded
—	NCT02296047	Dec 2014 → May 2015	chronic obstructive pulmonary disease	Zhujiang Hospital	Completed	No outcome recorded
—	NCT03062904	Feb 2014 → Dec 2019	—	Assistance Publique - Hôpitaux de Paris	Unknown	No outcome recorded
—	NCT02551276	Nov 2013 → Nov 2014	upper limb hypertrophy	University of Copenhagen	Completed	No outcome recorded
—	NCT02218398	May 2013 → Jun 2015	chronic obstructive pulmonary disease	Beijing Chao Yang Hospital	Unknown	No outcome recorded
—	NCT01655199	Sep 2012 → Jul 2014	chronic obstructive pulmonary disease	Laval University	Unknown	No outcome recorded
—	NCT01799109	Nov 2011 → Jan 2012	asthma	Chongqing Medical University	Completed	No outcome recorded
—	NCT01323010	Sep 2011 → Dec 2013	asthma	University of Sao Paulo	Completed	No outcome recorded
—	NCT01521572	Jun 2011 → Jan 2012	obstructive lung disease	Rio de Janeiro State University	Unknown	No outcome recorded
—	NCT01255449	Dec 2010 → Mar 2012	disease related to hematopoietic stem cell transplant, transplant-related bronchiolitis obliterans	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	Completed	No outcome recorded
—	NCT01196377	Sep → Oct 2010	acute asthma	Vanderbilt University Medical Center	Completed	No outcome recorded
—	NCT01067534	Feb 2010 → Jan 2011	isoproterenol-mediated vasodilatation	University of Patras	Completed	No outcome recorded
—	NCT01880723	May 2009 → Jul 2012	cystic fibrosis	University of Arizona	Completed	No outcome recorded
—	NCT00498251	Sep 2004 → Jun 2007	acute lung injury	University Hospital, Geneva	Completed	No outcome recorded
—	NCT00114478	Nov 2003 → May 2006	bronchiolitis	Kern Medical Center	Unknown	No outcome recorded
—	NCT00162422	Aug 2003 → ?	asthma	Hadassah Medical Organization	Unknown	No outcome recorded
—	NCT00162487	Aug 2002 → ?	chronic renal failure syndrome	Hadassah Medical Organization	Unknown	No outcome recorded
—	NCT00039988	Nov 2001 → Mar 2006	multiple sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00027391	Sep 2001 → Aug 2004	muscular dystrophy, scapulohumeral	FDA Office of Orphan Products Development	Completed	No outcome recorded
—	NCT00162396	Aug 1999 → ?	asthma	Hadassah Medical Organization	Unknown	No outcome recorded
—	NCT00004685	Jan 1998 → Sep 2000	facioscapulohumeral muscular dystrophy	Ohio State University	Completed	No outcome recorded
—	NCT00005110	—	cystic fibrosis	National Center for Research Resources (NCRR)	Suspended	No outcome recorded

Also used as a comparator or background therapy in 223 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT04901715 Comparator	Jun 2021 → Jul 2024	primary ciliary dyskinesia	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 114 trials
Phase 1	NCT05366764 Background	Jun 2022 → Feb 2023	asthma	Sanofi	Completed	No outcome recorded
Phase 1	NCT05035862 Background	Mar → Dec 2022	asthma	Emory University	Terminated	No outcome recorded
Phase 1	NCT04929626 Comparator	Jan → Nov 2022	status asthmaticus	Ziauddin University	Completed	No outcome recorded
Phase 1	NCT04848662 Background	May → Jul 2021	asthma	Bond Avillion 2 Development LP	Completed	No outcome recorded
Phase 1	NCT04488705 Background	Aug 2020 → May 2021	—	Enterprise Therapeutics Ltd	Completed	No outcome recorded
Phase 1	NCT03934333 Background	May → Sep 2019	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT02401074 Background	Nov 2018 → Jun 2020	asthma	Lu Yuan Lee	Withdrawn	No outcome recorded
Phase 1	NCT03287310 Background	Oct 2017 → Jul 2019	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT03059017 Comparator	Feb 2017	lung disorder	British University In Egypt	Completed	No outcome recorded
Phase 1	NCT02872597 Background	Sep 2016 → Aug 2018	status asthmaticus	University Hospitals Cleveland Medical Center	Completed	No outcome recorded
Phase 1	NCT05006235 Comparator	Feb 2014 → Dec 2015	persistent tachypnoe of infancy, usual	Ahmed Noaman	Completed	No outcome recorded
Phase 1	NCT00869596 Comparator	Mar → Sep 2009	lower respiratory tract disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00673621 Background	May → Nov 2008	asthma, diabetes mellitus	Mannkind Corporation	Completed	No outcome recorded
Phase 1	NCT00565591 Comparator	Nov 2007 → Jan 2008	allergic asthma	Respirics Inc.	Completed	No outcome recorded

Phase 1/21 trial
Phase 1/2	NCT04433104 Background	Jun 2020 → Jul 2021	chronic obstructive pulmonary disease	Vinmec Research Institute of Stem Cell and Gene Technology	Completed	No outcome recorded
Phase 239 trials
Phase 2	NCT06676319 Background	Nov 2024 → Jun 2027 expected	asthma	Sanofi	Active not recruiting	No outcome recorded
Phase 2	NCT06482294 Background	Jun 2024 → May 2025	asthma	Università degli Studi di Ferrara	Unknown	No outcome recorded
Phase 2	NCT06095258 Comparator	Dec 2023 → Nov 2025	long COVID-19	Chinese University of Hong Kong	Unknown	No outcome recorded
Phase 2	NCT05819541 Background	Oct 2023 → Mar 2026	status asthmaticus	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 2	NCT05987371 Background	Aug 2023 → Jan 2024	chronic obstructive pulmonary disease	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT05363670 Comparator	Jul 2022 → Feb 2024	asthma	ARS Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT04589663 Background	Jun 2021 → Apr 2022	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT04643158 Background	Mar 2021 → Jul 2023	asthma	AstraZeneca	Terminated	No outcome recorded
Phase 2	NCT04565847 Comparator	Nov 2020 → Dec 2021	—	McMaster University	Completed	No outcome recorded
Phase 2	NCT03707678 Background	Jan → Dec 2019	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 2	NCT03345407 Background	Nov 2017 → Jan 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Terminated	No outcome recorded
Phase 2	NCT03012061 Background	Jan 2017 → May 2018	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT02794519 Background	Sep → Oct 2016	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 2	NCT02720081 Background	May 2016 → Aug 2017	asthma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT02573870 Background	Dec 2015 → Jul 2016	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT02479412 Background	Jun 2015 → Feb 2016	asthma	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT02427165 Comparator	Apr → Nov 2015	asthma	Verona Pharma, Inc.	Completed	No outcome recorded
Phase 2	NCT02299375 Background	Dec 2014 → Jun 2016	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT02271334 Comparator	Aug → Oct 2014	asthma	Amphastar Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT02210806 Comparator	Jul → Sep 2014	asthma	Amphastar Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT02108743 Comparator	Jun 2014 → Jul 2016	idiopathic pulmonary arterial hypertension	American Medical Association Foundation	Withdrawn	No outcome recorded
Phase 2	NCT01899144 Comparator	Jul → Oct 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 2	NCT01854047 Background	Jun 2013 → Nov 2014	asthma	Sanofi	Completed	No outcome recorded
Phase 2	NCT02162784 Comparator	Feb 2013 → Aug 2014	asthma	Intech Biopharm Ltd.	Completed	No outcome recorded
Phase 2	NCT01772368 Background	Jan → Jun 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 2	NCT01615874 Background	Jan → Sep 2013	asthma	Organon and Co	Withdrawn	No outcome recorded
Phase 2	NCT01641692 Background	May 2012 → Feb 2013	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01576718 Background	Apr 2012 → Jul 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 2	NCT01479621 Background	Jan 2012 → Jul 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 2	NCT01425801 Comparator	Aug 2011 → Feb 2012	asthma	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT01312961 Background	Mar 2011 → Oct 2012	asthma	Sanofi	Completed	No outcome recorded
Phase 2	NCT00677729 Comparator	Nov 2008 → Apr 2009	bronchiolitis	Queen's University	Completed	No outcome recorded
Phase 2	NCT00632502 Background	May 2008 → Feb 2009	asthma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00545272 Background	Oct 2007 → Apr 2008	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00557466 Background	Oct 2007 → May 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 2	NCT00441701 Background	Dec 2006 → Oct 2008	chronic obstructive pulmonary disease	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 2	NCT00410150 Background	Apr 2006 → Dec 2007	status asthmaticus	Children's Hospital Medical Center, Cincinnati	Terminated	No outcome recorded
Phase 2	NCT00117182 Background	Jul 2005 → Aug 2006	chronic obstructive pulmonary disease	Syntara	Completed	No outcome recorded
Phase 2	NCT00054964 Comparator	Mar → Aug 2003	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT06657066 Background	Dec 2021 → Apr 2022	asthma	King Edward Medical University	Completed	No outcome recorded
Phase 2/3	NCT00434993 Comparator	Aug 2007 → Sep 2008	adult acute respiratory distress syndrome	National Heart, Lung, and Blood Institute (NHLBI)	Terminated	No outcome recorded
Phase 2/3	NCT00633919 Comparator	Jul 2006 → Dec 2008	allergic disease	ALK-Abelló A/S	Completed	No outcome recorded
Phase 360 trials
Phase 3	NCT05776927 Background	May 2026 → Dec 2028 expected	asthma	Novartis Pharmaceuticals	Not yet recruiting	No outcome recorded
Phase 3	NCT06473779 Background	Sep 2024 → Jun 2027 expected	asthma	AstraZeneca	Active not recruiting	No outcome recorded
Phase 3	NCT06502366 Comparator	Jul 2024 → Mar 2026 overdue	asthma	AstraZeneca	Active not recruiting	No outcome recorded
Phase 3	NCT06429475 Comparator	Jun 2024 → Dec 2028 expected	asthma	University of KwaZulu	Recruiting	No outcome recorded
Phase 3	NCT06261957 Comparator	May 2024 → Sep 2025	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT06052267 Comparator	Aug 2023 → Oct 2026 expected	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Active not recruiting	No outcome recorded
Phase 3	NCT05884970 Comparator	Mar 2023 → Mar 2024	childhood onset asthma	Canisius-Wilhelmina Hospital	Unknown	No outcome recorded
Phase 3	NCT05555290 Background	Sep 2022 → Nov 2024	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT05527704 Comparator	Dec 2021 → Nov 2025 overdue	pulmonary hypertension, neonatal, respiratory failure	Medical University of Warsaw	Active not recruiting	No outcome recorded
Phase 3	NCT04446637 Comparator	Sep 2021 → Sep 2022	chronic obstructive pulmonary disease	Neutec Ar-Ge San ve Tic A.Ş	Withdrawn	No outcome recorded
Phase 3	NCT03847896 Comparator	Mar 2019 → Jul 2021	asthma	Bond Avillion 2 Development LP	Completed	No outcome recorded
Phase 3	NCT03376932 Background	Jan 2019 → Feb 2021	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 3	NCT03769090 Comparator	Dec 2018 → Aug 2021	asthma	Bond Avillion 2 Development LP	Completed	No outcome recorded
Phase 3	NCT03562195 Background	Aug 2018 → Sep 2022	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT03745261 Background	Jun 2018 → Dec 2019	chronic obstructive pulmonary disease	Henan University of Traditional Chinese Medicine	Unknown	No outcome recorded
Phase 3	NCT03468790 Background	May 2018 → Jan 2021	allergic asthma	Shanghai Biomabs Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT03549897 Comparator	Mar → Aug 2018	asthma	Amneal Ireland Limited	Unknown	No outcome recorded
Phase 3	NCT03137303 Background	Jul 2017 → Sep 2019	—	University of Illinois at Chicago	Completed	No outcome recorded
Phase 3	NCT03184987 Background	Jun 2017 → Jun 2019	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02924688 Background	Oct 2016 → Feb 2019	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02729051 Background	Jun 2016 → May 2017	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02731846 Background	Jun → Nov 2016	chronic obstructive pulmonary disease	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 3	NCT02741271 Background	May 2016 → Dec 2017	asthma	Organon and Co	Completed	No outcome recorded
Phase 3	NCT02528214 Background	Oct 2015 → Sep 2017	asthma	Sanofi	Completed	No outcome recorded
Phase 3	NCT02483975 Background	Oct 2015 → Jun 2016	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02513160 Background	Sep 2015 → Mar 2016	chronic asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02502734 Background	Sep → Dec 2015	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02478398 Background	Jul 2015 → Nov 2018	seasonal allergic rhinitis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT02477397 Comparator	May 2015 → Jun 2019	chronic obstructive pulmonary disease	University Medical Center Groningen	Unknown	No outcome recorded
Phase 3	NCT02414854 Background	Apr 2015 → Jul 2017	asthma	Sanofi	Completed	No outcome recorded
Phase 3	NCT02127697 Background	Mar 2015 → May 2017	asthma	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 3	NCT02345161 Background	Jan 2015 → Apr 2016	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02257385 Background	Oct 2014 → May 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02175771 Background	Jul 2014 → Jul 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02139644 Background	Jun 2014 → Sep 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02141854 Background	Jun 2014 → Sep 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02040779 Background	Dec 2013 → Dec 2014	chronic asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02031640 Background	Dec 2013 → Nov 2014	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02040766 Background	Dec 2013 → Feb 2016	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT01987219 Comparator	Mar 2013 → Dec 2014	Riley-Day syndrome	NYU Langone Health	Completed	No outcome recorded
Phase 3	NCT01687296 Background	Nov 2012 → Jun 2013	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01706328 Background	Oct 2012 → Jun 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01613326 Background	Jun 2012 → Jan 2013	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01490125 Background	Oct 2011 → Aug 2012	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01431950 Background	Sep 2011 → Oct 2012	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01323621 Background	Mar 2011 → Jan 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01313494 Background	Mar 2011 → May 2012	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01120691 Background	Apr 2010 → Jul 2012	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01019694 Comparator	Nov 2009 → Apr 2011	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00861926 Comparator	Mar 2009 → Dec 2010	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT00550550 Background	Nov 2007 → Sep 2009	allergic rhinitis, conjunctivitis	ALK-Abelló A/S	Completed	No outcome recorded
Phase 3	NCT00562159 Background	Nov 2007 → Sep 2009	allergic disease, conjunctivitis, rhinitis	ALK-Abelló A/S	Completed	No outcome recorded
Phase 3	NCT00588406 Background	Sep 2007 → Dec 2009	asthma	Northwell Health	Completed	No outcome recorded
Phase 3	NCT00394329 Background	Nov 2006 → Dec 2011	asthma	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 3	NCT00384189 Comparator	Sep 2006 → Aug 2007	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00497523 Comparator	Mar 2006 → Jan 2007	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT00628758 Background	Dec 2005 → Sep 2008	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00646620 Comparator	Apr → Sep 2003	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00646009 Comparator	Mar → Aug 2003	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00685126 Comparator	Feb 2001 → Jul 2002	reactive airway disease	Sumitomo Pharma America, Inc.	Completed	No outcome recorded

Phase 460 trials
Phase 4	NCT07052942 Comparator	Aug 2025 → Nov 2029 expected	acute asthma	DARTNet Institute	Recruiting	No outcome recorded
Phase 4	NCT06816342 Comparator	Nov 2024 → Feb 2025 overdue	asthma	Beni-Suef University	Recruiting	No outcome recorded
Phase 4	NCT07633223 Comparator	Sep 2024 → Aug 2025	asthma	Beni-Suef University	Completed	No outcome recorded
Phase 4	NCT06152653 Background	Apr 2024 → Apr 2027 expected	asthma, chronic obstructive pulmonary disease	University of California, San Francisco	Recruiting	No outcome recorded
Phase 4	NCT06272370 Comparator	Feb → Sep 2024	asthma, hypersensitivity reaction disease, obstructive lung disease, respiratory tract infectious disorder	DARTNet Institute	Completed	No outcome recorded
Phase 4	NCT05977699 Comparator	Jan → Nov 2024	asthma	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT06918418 Comparator	Jan → Jun 2024	acute asthma	Children's Hospital and Institute of Child Health, Multan	Completed	No outcome recorded
Phase 4	NCT05667727 Comparator	Oct 2023 → Jun 2025	childhood onset asthma	Oman Medical Speciality Board	Completed	No outcome recorded
Phase 4	NCT06036823 Comparator	Oct 2023 → Sep 2025	mineral metabolism disease	Oman Medical Speciality Board	Completed	No outcome recorded
Phase 4	NCT05173584 Comparator	Nov → Dec 2021	—	University of Aleppo	Unknown	No outcome recorded
Phase 4	NCT04584034 Comparator	Sep 2021 → Apr 2023	—	UMC Utrecht	Withdrawn	No outcome recorded
Phase 4	NCT04276233 Background	Jun 2021 → Oct 2023	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT04655170 Comparator	Dec 2020 → Jan 2023 overdue	chronic obstructive pulmonary disease	University of Tennessee Graduate School of Medicine	Recruiting	No outcome recorded
Phase 4	NCT04159519 Background	Jul 2020 → Jan 2023	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT03880903 Background	Jul 2020 → Mar 2021	acute bronchiolitis	Assiut University	Unknown	No outcome recorded
Phase 4	NCT03952286 Background	Aug 2019 → Dec 2020	childhood onset asthma	University of Arizona	Completed	No outcome recorded
Phase 4	NCT03822637 Background	Feb 2019 → Feb 2025	asthma	University of California, San Francisco	Terminated	No outcome recorded
Phase 4	NCT04750603 Comparator	Dec 2018 → Jan 2020	childhood onset asthma	Rambam Health Care Campus	Completed	No outcome recorded
Phase 4	NCT03478683 Background	Jun 2018 → Mar 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03478696 Background	Jun 2018 → Mar 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03474081 Background	Mar 2018 → Jul 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03363191 Background	Mar 2018 → May 2019	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 4	NCT03380429 Background	Jan 2018 → Jan 2019	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03405090 Comparator	Sep 2017 → Mar 2022	chronic obstructive pulmonary disease	Dr. Denis O'Donnell	Completed	No outcome recorded
Phase 4	NCT02889809 Background	Jul 2017 → Apr 2021	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03333395 Comparator	Feb → Sep 2017	—	Ain Shams University	Completed	No outcome recorded
Phase 4	NCT02799784 Background	Jul 2016 → Apr 2017	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02508311 Comparator	Jun 2016 → Mar 2022	myopathy, spinal cord injury	VA Office of Research and Development	Terminated	No outcome recorded
Phase 4	NCT02319564 Comparator	Apr → Oct 2016	—	University of Calgary	Withdrawn	No outcome recorded
Phase 4	NCT02654145 Background	Mar 2016 → May 2017	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02584738 Background	Sep 2015 → Jan 2016	asthma	Hospital General Naval de Alta Especialidad - Escuela Medico Naval	Unknown	No outcome recorded
Phase 4	NCT02371629 Background	Jun 2015 → Nov 2016	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02275052 Background	Jan 2015 → Jun 2016	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02233803 Background	Nov 2014 → Dec 2015	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02257372 Background	Sep 2014 → Mar 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01997463 Background	Aug 2014 → Jun 2016	childhood onset asthma	University of Arizona	Completed	No outcome recorded
Phase 4	NCT01978418 Comparator	Nov 2013 → Sep 2015	lung disorder	Sture Andersson	Unknown	No outcome recorded
Phase 4	NCT01951378 Comparator	Sep 2013 → Jun 2016	asthma	Seton Healthcare Family	Terminated	No outcome recorded
Phase 4	NCT01907334 Comparator	Aug 2013 → May 2014	asthma	University of Florida	Completed	No outcome recorded
Phase 4	NCT01922271 Background	Aug 2013 → Jan 2014	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01691482 Comparator	Jul → Oct 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01471340 Background	Jan 2012 → Nov 2016	asthma	Organon and Co	Completed	No outcome recorded
Phase 4	NCT01515995 Background	Jan 2012 → Oct 2015	asthma	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT01338311 Comparator	Mar 2011 → Mar 2012	asthma	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT00831376 Comparator	Jan 2009 → Apr 2012	asthma	University of Dundee	Completed	No outcome recorded
Phase 4	NCT00830882 Comparator	Jan 2009 → Jan 2010	asthma	University of Dundee	Withdrawn	No outcome recorded
Phase 4	NCT00900874 Comparator	Jan 2009 → May 2010	asthma	All India Institute of Medical Sciences	Unknown	No outcome recorded
Phase 4	NCT01151579 Comparator	Dec 2008 → Nov 2009	chronic obstructive pulmonary disease, infectious disease with sepsis	Fahim Khorfan, MD	Completed	No outcome recorded
Phase 4	NCT00911651 Comparator	Jun → Jul 2008	chronic obstructive pulmonary disease	University Hospital, Antwerp	Completed	No outcome recorded
Phase 4	NCT00567476 Comparator	Nov 2007 → Apr 2010	asthma	Novartis	Completed	No outcome recorded
Phase 4	NCT00487773 Comparator	Sep 2007 → Sep 2008	asthma	Medical University of Lodz	Completed	No outcome recorded
Phase 4	NCT00530062 Comparator	Jul 2007 → Oct 2008	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 4	NCT00393367 Background	Dec 2006 → Nov 2007	acute asthma, reactive airway disease	Children's Hospital of Philadelphia	Completed	No outcome recorded
Phase 4	NCT00363480 Background	May 2006 → Sep 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01091337 Comparator	May 2006 → Sep 2009	asthma	Otsuka Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 4	NCT00315744 Background	Nov 2004 → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00600639 Background	Jan 2004 → Dec 2007	acute respiratory failure	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Terminated	No outcome recorded
Phase 4	NCT00070707 Background	Apr → Nov 2003	asthma, seasonal allergic rhinitis	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00667797 Comparator	Mar 2003 → May 2005	asthma, chronic obstructive pulmonary disease	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 4	NCT00189436 Comparator	Mar 2003 → Jan 2009	asthma	Deborah Gentile	Completed	No outcome recorded

Phase not applicable45 trials
—	NCT07350421 Comparator	Jan 2026 → Jan 2027 expected	—	Latakia University	Not yet recruiting	No outcome recorded
—	NCT07037511 Comparator	Oct 2025 → Dec 2029 expected	asthma	University of British Columbia	Recruiting	No outcome recorded
—	NCT06609941 Background	Jun 2024 → Jan 2025 overdue	asthma	Foundation University Islamabad	Recruiting	No outcome recorded
—	NCT05550402 Comparator	Feb → Jun 2024	asthma, obstructive lung disease, parasympathetic nervous system disorder	Hat Yai Medical Education Center	Unknown	No outcome recorded
—	NCT05724745 Background	May 2023 → May 2028 expected	asthma, chronic obstructive pulmonary disease	French Alternative Energies and Atomic Energy Commission	Recruiting	No outcome recorded
—	NCT05930847 Background	Feb → Apr 2022	childhood onset asthma	Ege University	Completed	No outcome recorded
—	NCT05099107 Comparator	Oct 2021 → Mar 2025	centronuclear myopathy, nemaline myopathy, neuromuscular disease	Vastra Gotaland Region	Completed	No outcome recorded
—	NCT02509299 Background	Sep → Nov 2019	chronic obstructive pulmonary disease	University of Granada	Completed	No outcome recorded
—	NCT03902106 Comparator	Mar 2019 → Jun 2021	—	University of Copenhagen	Unknown	No outcome recorded
—	NCT03620422 Comparator	Jan 2019 → Jan 2020	asthma	McMaster University	Completed	No outcome recorded
—	NCT03814954 Comparator	Jan 2019 → Aug 2021	—	Makassed General Hospital	Completed	No outcome recorded
—	NCT03842839 Background	Oct 2018 → Dec 2022	—	Guangzhou Institute of Respiratory Disease	Unknown	No outcome recorded
—	NCT03556683 Background	Oct 2018 → Jun 2024	asthma	University of North Carolina, Chapel Hill	Completed	No outcome recorded
—	NCT03296579 Background	Jun → Nov 2018	acute asthma, childhood onset asthma	University of British Columbia	Unknown	No outcome recorded
—	NCT03522831 Comparator	May 2018 → Dec 2027 expected	cystic fibrosis, lung disorder	University of British Columbia	Active not recruiting	No outcome recorded
—	NCT03430505 Comparator	Jun 2017 → Jul 2018	asthma	University of Nove de Julho	Completed	No outcome recorded
—	NCT02790047 Background	Oct 2016 → Jan 2018	chronic obstructive pulmonary disease	Khon Kaen University	Unknown	No outcome recorded
—	NCT02766673 Comparator	Aug 2016 → Jun 2018	bronchopulmonary dysplasia	Children's Hospital of Philadelphia	Completed	No outcome recorded
—	NCT02686086 Comparator	Feb 2016 → Jul 2017	chronic obstructive pulmonary disease	Beaumont Hospital	Completed	No outcome recorded
—	NCT02499887 Background	Jan → Sep 2016	asthma, chronic obstructive pulmonary disease	State University of New York at Buffalo	Terminated	No outcome recorded
—	NCT02566902 Background	Oct 2015 → Jun 2017	asthma	Seton Healthcare Family	Completed	No outcome recorded
—	NCT02523833 Background	Sep 2015 → Jun 2017	hypersensitivity pneumonitis	University of Sao Paulo General Hospital	Completed	No outcome recorded
—	NCT02515318 Comparator	Sep 2015 → Mar 2017	chronic obstructive pulmonary disease	University of Granada	Unknown	No outcome recorded
—	NCT02458482 Comparator	Jul 2015 → Nov 2020	asthma	Vanderbilt University Medical Center	Withdrawn	No outcome recorded
—	NCT02252302 Comparator	May 2015 → Aug 2016	exercise-induced bronchoconstriction	University of British Columbia	Completed	No outcome recorded
—	NCT02073747 Comparator	Apr → Jul 2015	asthma	University Medical Center of Southern Nevada	Completed	No outcome recorded
—	NCT02159196 Comparator	Jul 2014 → Mar 2017	respiratory failure	Academic Medical Center - University of Amsterdam	Completed	No outcome recorded
—	NCT02341573 Comparator	Mar 2013 → Jun 2015	childhood onset asthma	Children's Hospital of Fudan University	Completed	No outcome recorded
—	NCT01714401 Comparator	Mar 2012 → May 2013	—	Medical University of Gdansk	Completed	No outcome recorded
—	NCT02453750 Background	Feb 2012 → Oct 2013	congenital diaphragmatic hernia	The Hospital for Sick Children	Completed	No outcome recorded
—	NCT02069665 Comparator	Dec 2011 → Jul 2013	pneumonia	Liaoning University of Traditional Chinese Medicine	Completed	No outcome recorded
—	NCT01856959 Comparator	Nov 2011 → Mar 2013	asthma	Chongqing Medical University	Completed	No outcome recorded
—	NCT01447069 Comparator	Oct 2011 → Mar 2012	cardiomyopathy, heart failure	Rabin Medical Center	Unknown	No outcome recorded
—	NCT01415596 Comparator	Aug 2011 → Aug 2012	—	Bispebjerg Hospital	Unknown	No outcome recorded
—	NCT01187589 Background	Dec 2010 → Sep 2011	chronic obstructive pulmonary disease	Respinova LTD	Completed	No outcome recorded
—	NCT01238848 Background	Dec 2010 → Oct 2011	acute bronchiolitis	Hospital General de Niños Pedro de Elizalde	Completed	No outcome recorded
—	NCT00981851 Comparator	Sep 2009 → May 2011	cardiovascular disorder, chronic obstructive pulmonary disease	Radboud University Medical Center	Completed	No outcome recorded
—	NCT01073527 Comparator	Jan 2009 → Jul 2011	asthma	Wolfson Medical Center	Completed	No outcome recorded
—	NCT00876135 Comparator	Dec 2008 → May 2013	asthma	Laval University	Completed	No outcome recorded
—	NCT00608790 Background	Feb 2008 → Dec 2012	tuberculosis	University of Cape Town	Unknown	No outcome recorded
—	NCT00521222 Background	Jun 2007 → Nov 2010	asthma	Columbia University	Completed	No outcome recorded
—	NCT00388739 Background	Nov 2006	asthma	Baylor College of Medicine	Withdrawn	No outcome recorded
—	NCT00180843 Comparator	Sep 2005 → Feb 2008	chronic obstructive pulmonary disease	Imperial College London	Terminated	No outcome recorded
—	NCT01143688 Comparator	Jan 2005 → Jan 2009	—	Brigham and Women's Hospital	Completed	No outcome recorded
—	NCT00319488 Comparator	Feb 2004 → Nov 2006	asthma, lung disorder	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded

Press releases naming this drug 13 releases

Date	Issuer	Release
2022-09-07	Teva Branded Pharmaceutical Products R&D, Inc.	CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management tevapharm.com ↗
2022-08-29	Teva Branded Pharmaceutical Products R&D, Inc.	Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022 tevapharm.com ↗
2022-05-17	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges tevapharm.com ↗
2022-05-12	Teva Branded Pharmaceutical Products R&D, Inc.	Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting tevapharm.com ↗
2020-07-13	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Availability of ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD tevapharm.com ↗
2018-12-21	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder tevapharm.com ↗
2016-04-29	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Approval of ProAir RespiClick® (albuterol sulfate) Inhalation Powder for Pediatric Asthma Patients Ages 4 to 11 tevapharm.com ↗
2015-09-10	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Acceptance of a Supplemental New Drug Application for ProAir® RespiClick (albuterol sulfate) Inhalation Powder for Pediatric Patients tevapharm.com ↗
2014-11-07	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Presents Data for Investigational Short-Acting Beta-Agonist Inhaler (Albuterol MDPI) at 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology tevapharm.com ↗
2014-07-14	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Acceptance of NDA Filing for Investigational Short-Acting Beta-Agonist (SABA) Inhaler (Albuterol MDPI) tevapharm.com ↗
2014-06-20	Otsuka Pharmaceutical Development & Commercialization, Inc.	Meptin, a Fast-acting Bronchodilator to Treat Asthma and COPD, Will Become Available in Japan on July 2 in a New Form as Meptin Swinghaler 10μg 100Puffs®®® otsuka.co.jp ↗
2014-02-17	Otsuka Pharmaceutical Development & Commercialization, Inc.	Meptin Swinghaler, Easy-to-inhale Bronchodilator for COPD and Asthma Patients, Approved in Japan otsuka.co.jp ↗
2008-09-24	Teva Branded Pharmaceutical Products R&D, Inc.	Teva's Proair® HFA, the Market Leading Albuterol Inhaler, Receives New Pediatric Indication tevapharm.com ↗

Evidence & citations 58 cited values

Every value below carries the sentence it was read from. 433 sources stand behind the page.

Field	Value	Cited text
Known as	salbutamol	“A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of...” NCT01479621 ↗ 229 “A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of...” NCT01576718 ↗ “A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of...” NCT02139644 ↗ “Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or...” NCT02513160 ↗ “A Study Designed to Determine if the Drugs Albuterol (Salbutamol) and Fluticasone Have an Effect on the Pharmacokinetics of the Investigational Product Technosphere® Insulin...” NCT00674050 ↗ “Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma...” NCT02040766 ↗ “Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma...” NCT02040779 ↗ “Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.” NCT03169504 ↗ “In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods.” NCT04643158 ↗ “Three concentrations of topical salbutamol gel will be compared, in a group-wise fashion, with a placebo administration at one incision site on each arm of the trial subjects.” NCT03514615 ↗ “Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1” NCT02345161 ↗ “The salbutamol collected on the filter was extracted with 90% acetonitrile and sonicated for 3 minutes, a process validated to recover the full drug dose.” NCT06816342 ↗ “Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.” NCT03474081 ↗ “A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory.” NCT02453750 ↗ “Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.” NCT02175771 ↗ “Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms” NCT00632502 ↗ “One year Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.” NCT02477397 ↗ “Albuterol/salbutamol will be supplied as an inhalation spray via metered dose inhaler and will be issued for reversibility testing at Visit 1.” NCT02799784 ↗ “All subjects will be provided albuterol/salbutamol inhalation aerosol, to use as needed to treat acute asthma symptoms throughout the study.” NCT02483975 ↗ “Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication” NCT02731846 ↗ “Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed.” NCT02275052 ↗ “Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.” NCT03478683 ↗ “Rescue medication (albuterol/salbutamol) was dispensed at each visit, if needed, as determined by the investigational center personnel.” NCT02141854 ↗ “Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.” NCT02794519 ↗ “PT027 is a fixed-dose combination of albuterol (salbutamol) and budesonide in a single pressurized metered-dose inhaler.” PMID 34699967 ↗ Oct 2021 “Albuterol/salbutamol is to be administered via metered-dose inhaler as a rescue drug on need basis throughout the study.” NCT03012061 ↗ “Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.” NCT00567476 ↗ “Any therapy that is prescribed as per asthma guidelines i.e. beclomethasone, budesonide and salbutamol, montelukast etc” NCT06429475 ↗ “Test of Bronchodilatation (combined Salbutamol 200μg and Ipratropium bromure 80μg; 2 inhalations): wait 30 min and then” NCT03062904 ↗ “Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.” NCT02654145 ↗ “Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.” NCT02729051 ↗ “Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief” NCT00441701 ↗ “Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)” NCT04589663 ↗ “100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).” NCT00557466 ↗ “100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).” NCT00545272 ↗ “Albuterol/Salbutamol MDI will be administered for symptom relief from screening to the end of the study.” NCT03707678 ↗ “In addition, all subjects will be provided with albuterol/salbutamol for relief of asthma symptoms.” NCT01431950 ↗ “Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.” NCT03345407 ↗ “albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed” NCT01615874 ↗ “Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study.” NCT02257385 ↗ “Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation” NCT03524066 ↗ “Salbutamol/albuterol was available for rescue medication use throughout the study.” NCT01120691 ↗ “0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer” NCT03405090 ↗ “Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.” NCT02889809 ↗ “Albuterol/salbutamol will be delivered as a rescue medication via MDI.” NCT03376932 ↗ “Short acting inhaled β2 agonists ( salbutamol and terbutaline)” NCT02515318 ↗ “Short acting inhaled β2 agonists ( salbutamol and terbutaline)” NCT02509299 ↗ “Albuterol (salbutamol) is a widely used asthma medication” NCT00385359 ↗ “400 mcg salbutamol administered per metered dose inhaler” NCT04914273 ↗ “of Salbutamol Sulfate, 288 mcg of Ipratropium Bromide” NCT02173678 ↗ “Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation” NCT02720081 ↗ “Combivent®, ipratropium 0.5 mg + salbutamol 2.5 mg” NCT00354354 ↗ “Salbutamol inhaler (Short acting bronchodilator)” NCT06609941 ↗ “Albuterol/salbutamol Metered Dose Inhaler (MDI)” NCT02257372 ↗ “Ventolin® MDI * Ingredient: Salbutamol sulfate” NCT01076322 ↗ “Albuterol 90 mcg /salbutamol 100 mcg HFA MDI” NCT01471340 ↗ “Salbutamol 100μg / Albuterol 90μg” NCT05776927 ↗ “Salbutamol(Albuterol) Sulfate” NCT03098680 ↗ “Albuterol/salbutamol (daily)” NCT01691482 ↗ “Salbutamol 200 µg/dose dmDPI” NCT05084222 ↗ “Salbutamol (oral or inhaler)” NCT02790047 ↗ “Drug: Albuterol/Salbutamol” NCT02414854 ↗ “Albuterol/Salbutamol PRN” NCT02741271 ↗ “Salbutamol, Terbutaline” NCT04433104 ↗ “albuterol (salbutamol)” NCT00114478 ↗ “salbutamol inhalation” NCT03208894 ↗ “Albuterol/salbutamol” NCT02924688 ↗ “albuterol/salbutamol” NCT03478696 ↗ “Albuterol/salbutamol” NCT02031640 ↗ “Albuterol/Salbutamol” NCT02528214 ↗ NCT00180843 ↗ NCT03436225 ↗ NCT04402658 ↗ NCT07350421 ↗ NCT05932316 ↗ NCT02877537 ↗ NCT00600639 ↗ NCT04488705 ↗ NCT01687296 ↗ NCT03880903 ↗ NCT00363480 ↗ NCT01447069 ↗ NCT00117182 ↗ NCT00981851 ↗ NCT04012138 ↗ NCT06482294 ↗ NCT06921291 ↗ NCT02584738 ↗ NCT06473779 ↗ NCT06657066 ↗ NCT02405598 ↗ NCT00487773 ↗ NCT02542254 ↗ NCT01067534 ↗ NCT01313494 ↗ NCT06433921 ↗ NCT05099107 ↗ NCT06433908 ↗ NCT02523833 ↗ NCT06158893 ↗ NCT05914285 ↗ NCT03902106 ↗ NCT03449056 ↗ NCT02207452 ↗ NCT01096017 ↗ NCT01641692 ↗ NCT06139029 ↗ NCT02914652 ↗ NCT01903785 ↗ NCT01854047 ↗ NCT07378605 ↗ NCT00669617 ↗ NCT00549120 ↗ NCT03333395 ↗ NCT03842839 ↗ NCT00384189 ↗ NCT03363191 ↗ NCT04276233 ↗ NCT01073527 ↗ NCT00252863 ↗ NCT06754631 ↗ NCT01521572 ↗ NCT03924635 ↗ NCT02551276 ↗ NCT00440245 ↗ NCT05589441 ↗ NCT00673621 ↗ NCT02818270 ↗ NCT02252302 ↗ NCT01425801 ↗ NCT05087693 ↗ NCT03493503 ↗ NCT00861926 ↗ NCT07037511 ↗ NCT02371629 ↗ NCT02925130 ↗ NCT03620422 ↗ NCT03814954 ↗ NCT00358488 ↗ NCT01415596 ↗ NCT06027606 ↗ NCT05786950 ↗ NCT05550402 ↗ NCT02235428 ↗ NCT05860244 ↗ NCT05366764 ↗ NCT04750603 ↗ NCT03914638 ↗ NCT01922271 ↗ NCT01836016 ↗ NCT03745261 ↗ NCT02233803 ↗ NCT02182713 ↗ NCT00315744 ↗ NCT02782052 ↗ NCT03199976 ↗ NCT04615611 ↗ NCT01457261 ↗ NCT01091337 ↗ NCT00911651 ↗ NCT01721291 ↗ NCT07436104 ↗ NCT02319564 ↗ NCT05006235 ↗ NCT01714401 ↗ NCT04584034 ↗ NCT02177253 ↗ NCT02427165 ↗ NCT01470755 ↗ NCT01984086 ↗ NCT01958814 ↗ NCT04565847 ↗ NCT03380429 ↗ NCT03522831 ↗ NCT01957293 ↗ NCT00633919 ↗ NCT00382889 ↗ NCT05884970 ↗ NCT00608790 ↗ NCT02479412 ↗ NCT03562195 ↗ NCT02502734 ↗ NCT05667727 ↗ NCT00273962 ↗ NCT05977699 ↗ NCT01490125 ↗ NCT03271905 ↗ NCT01323621 ↗ NCT07591558 ↗ NCT02069665 ↗ NCT01613326 ↗ NCT00498251 ↗ NCT00272753 ↗ NCT01338311 ↗ NCT00696540 ↗ NCT06426082 ↗ NCT03059017 ↗ NCT03044938 ↗ NCT00528723 ↗ NCT06815679 ↗ NCT00497523 ↗ NCT06918418 ↗ NCT06261957 ↗ NCT05527704 ↗ NCT04558190 ↗ NCT06276231 ↗ NCT00900874 ↗ NCT04446637 ↗ NCT00677729 ↗ NCT03184987 ↗ NCT03287310 ↗ NCT02127697 ↗ NCT02160548 ↗ NCT02296047 ↗ NCT05653024 ↗ NCT02159196 ↗ NCT03816267 ↗ NCT05724745 ↗ NCT06319183 ↗ NCT02299375 ↗ NCT03556683 ↗ NCT03296579 ↗ NCT01706328 ↗ NCT01655199 ↗ NCT05791565 ↗ NCT02686086 ↗ NCT06036823 ↗ NCT05987371 ↗ NCT01978418 ↗ NCT00783250 ↗
Known as	A004	“This 12-week clinical study evaluates the safety and efficacy of Albuterol Sulfate HFA Inhalation Aerosol (Albuterol-HFA, or: A004), Armstrong's proposed HFA formulation of...” NCT00635505 ↗
Known as	A006	“A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active control, Proventil-HFA (Albuterol Metered Dose Inhaler (MDI))” NCT01189396 ↗ 3 “A006 albuterol inhalation powder, 120 mcg/inhalation, one inhalation” NCT01174732 ↗ “A006, an Albuterol dry powder inhaler (DPI)” NCT01581177 ↗ NCT02271334 ↗
Known as	ABS	“This is a Phase 3B, 12-week, multicenter, open-label study to evaluate the relationship between albuterol sulfate (ABS) eMDPI and clinical asthma exacerbation (CAE) in adult...” NCT02969408 ↗ 2 “Albuterol sulfate (ABS) dry powder inhaler with an integrated electronic module (eMDPI)” NCT06664619 ↗ “fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination” NCT06290102 ↗
Known as	aerolin nebulis	“Nebulized bronchodilator drugs will be Salbutamol Sulfate (aerolin nebulis) and ipratropium bromide (atrovent) diluted in a saline solution (saline 0.9%) in 3 ml.” NCT03271905 ↗
Known as	ALB	“comparing the fixed combination of ipratropium and albuterol (IB+ALB) to albuterol alone (ALB).” PMID 18403223 ↗ Mar 2008
Known as	ALB-HFA	“albuterol hydrofluoroalkaline (ALB-HFA) alone after 4 weeks” PMID 27130202 ↗ Apr 2016
Known as	albuterol	“BACKGROUND: Treatment guidelines recommend the regular use of inhaled corticosteroids for patients with mild persistent asthma. We investigated whether the symptom-driven use...” PMID 17507703 ↗ May 2007 211 “Participants were randomly assigned in a 1:1 ratio to a fixed-dose combination of 180 μg of albuterol and 160 μg of budesonide (with each dose consisting of two inhaler...” PMID 40388330 ↗ May 2025 “participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid...” NCT06272370 ↗ “This study evaluates the efficacy, dose-ranging and safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 110 to 220 mcg per dose in comparison...” NCT02210806 ↗ “The aim is to asses that using Nebulized Hypertonic Saline with bronchodilators (albuterol) may reduce the days of hospitalization and improve clinical outcomes in patients...” NCT01238848 ↗ “The effects of albuterol delivered via AS MDI and Proventil on bronchodilation were equivalent, supporting the selection of AS MDI 180 µg to be taken into Phase III clinical...” PMID 34089147 ↗ Jun 2021 “The purpose of the project is to investigate whether the use of a WADA approved dose of salbutamol (albuterol/Ventoline) has a performance-enhancing effect on sprint...” NCT04402658 ↗ “All subjects received fluticasone furoate/vilanterol ELLIPTA dry-powder inhalers for maintenance and salbutamol/albuterol metered-dose inhalers for rescue, with a sensor...” PMID 33334936 ↗ Jun 2021 “In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods.” NCT04643158 ↗ “FDA approval of Airsupra (with both albuterol and budesonide in one inhaler) provides a unique opportunity to introduce ICS (along with albuterol) to ED patients with acute asthma.” NCT07166939 ↗ “Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period” NCT01641692 ↗ “Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms” NCT00632502 ↗ “Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 μg per puff. Two puffs to administer 160/180 μg dose.” NCT04848662 ↗ “Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.” NCT02794519 ↗ “Patients with moderate to severe COPD were randomized to ipratropium bromide/albuterol (20/100mcg) Respimat inhaler” PMID 20172704 ↗ Feb 2010 “Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief” NCT00441701 ↗ “salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.” NCT01490125 ↗ “100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).” NCT00557466 ↗ “When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.” NCT05555290 ↗ “100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).” NCT00545272 ↗ “Subjects will also be given a short-acting beta agonist, albuterol (2 puffs, 180 mcg) prior to bronchoscopy.” NCT02401074 ↗ “Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.” NCT03287310 ↗ “The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.” NCT00669617 ↗ “albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed” NCT01615874 ↗ “budesonide/albuterol sulfate pressurized inhalation suspension metered dose inhaler (BDA MDI)” NCT03934333 ↗ “the study intervention of 15 mg of albuterol diluted in 22 ml of magnesium sulfate solution” NCT01515995 ↗ “Salbutamol/albuterol was available for rescue medication use throughout the study.” NCT01120691 ↗ “Albuterol extended release belongs to a class of drugs known as bronchodilators.” NCT00755079 ↗ “salbutamol/albuterol given as a rescue medication via inhaler when needed” NCT01613326 ↗ “Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.” NCT02889809 ↗ “PROAIR® HFA (Albuterol Sulfate) Inhalation Aerosol, eq 90 mcg Base” NCT03549897 ↗ “Budesonide/albuterol pressurized inhalation suspension, HFO” NCT06502366 ↗ “or be converted to budesonide/albuterol as rescue therapy” NCT07052942 ↗ “Albuterol Syrup (1mL= Salbutamol 0.4mg, 60ml/bot)” NCT02405598 ↗ “Albuterol DPI with 180 mcg Albuterol/inhalation” NCT01189396 ↗ “albuterol hydrofluoroalkane (HFA) inhalers” PMID 27523719 ↗ Aug 2016 “as-needed albuterol 180 µg” PMID 41791845 ↗ Mar 2026 “Salbutamol (Albuterol)” NCT00673621 ↗ “Salbutamol (Albuterol)” NCT07350421 ↗ “salbutamol/ albuterol” NCT02127697 ↗ “Salbutamol/Albuterol” NCT03363191 ↗ “Salbutamol/albuterol” NCT01854047 ↗ “Albuterol” NCT03549897 ↗ NCT03478696 ↗ NCT06154304 ↗ NCT03707678 ↗ NCT06152653 ↗ NCT06563102 ↗ NCT04655170 ↗ NCT01907334 ↗ NCT02218398 ↗ NCT01203592 ↗ NCT05173584 ↗ NCT02885636 ↗ NCT02766673 ↗ NCT00869596 ↗ NCT02729051 ↗ NCT00634829 ↗ NCT02731846 ↗ NCT02275052 ↗ NCT01987219 ↗ NCT02720081 ↗ NCT02872597 ↗ NCT04677959 ↗ NCT02528214 ↗ NCT05819541 ↗ NCT06946264 ↗ NCT00325767 ↗ NCT00634517 ↗ NCT03430505 ↗ NCT00310401 ↗ NCT01691482 ↗ NCT01058863 ↗ NCT02740660 ↗ NCT04207840 ↗ NCT03643874 ↗ NCT02741271 ↗ NCT02040766 ↗ NCT02040779 ↗ NCT00054964 ↗ NCT03373409 ↗ NCT02031640 ↗ NCT01431950 ↗ NCT03474081 ↗ NCT00685126 ↗ NCT00361452 ↗ NCT01056159 ↗ NCT03478683 ↗ NCT02458482 ↗ NCT00462540 ↗ NCT03376932 ↗ NCT01255449 ↗ NCT04184609 ↗ NCT03480997 ↗ NCT02141854 ↗ NCT03098680 ↗ NCT02345161 ↗ NCT00359788 ↗ NCT00096616 ↗ NCT01187589 ↗ NCT00521222 ↗ NCT02414854 ↗ NCT00530062 ↗ NCT02108743 ↗ NCT02257372 ↗ NCT06471257 ↗ NCT02257385 ↗ NCT00674050 ↗ NCT01856959 ↗ NCT02924688 ↗ NCT00039988 ↗ NCT03586544 ↗ NCT01857323 ↗ NCT00649779 ↗ NCT02139644 ↗ NCT00388882 ↗ NCT03772223 ↗ NCT00818454 ↗ NCT00388739 ↗ NCT03889379 ↗ NCT02513160 ↗ NCT01880723 ↗ NCT00665600 ↗ NCT03822637 ↗ NCT00649987 ↗ NCT01424813 ↗ NCT01112241 ↗ NCT03890666 ↗ NCT01479621 ↗ NCT01698320 ↗ NCT00308685 ↗ NCT02566902 ↗ NCT06514157 ↗ NCT02508311 ↗ NCT01859624 ↗ NCT00577655 ↗ NCT01218009 ↗ NCT03012061 ↗ NCT01471340 ↗ NCT01895998 ↗ NCT01799538 ↗ NCT03769090 ↗ NCT01312961 ↗ NCT03256695 ↗ NCT01799109 ↗ NCT02678949 ↗ NCT00410150 ↗ NCT00550550 ↗ NCT01263197 ↗ NCT06676319 ↗ NCT02573870 ↗ NCT01581177 ↗ NCT01576718 ↗ NCT01252758 ↗ NCT01844401 ↗ NCT02073747 ↗ NCT03270332 ↗ NCT02175771 ↗ NCT02499887 ↗ NCT04234464 ↗ NCT03137303 ↗ NCT00004685 ↗ NCT01151579 ↗ NCT00273689 ↗ NCT01143688 ↗ NCT00940927 ↗ NCT01375361 ↗ NCT00027391 ↗ NCT01019694 ↗ NCT02135965 ↗ NCT06245551 ↗ NCT01772368 ↗ NCT00162396 ↗ NCT00085774 ↗ NCT00667797 ↗ NCT01323010 ↗ NCT00162422 ↗ NCT00162487 ↗ NCT00189436 ↗ NCT00646620 ↗ NCT04901715 ↗ NCT00646009 ↗ NCT06422689 ↗ NCT02162784 ↗ NCT01174732 ↗ NCT00588406 ↗ NCT05035862 ↗ NCT02126839 ↗ NCT02447250 ↗ NCT00000577 ↗ NCT01196377 ↗ NCT00434993 ↗ NCT03345407 ↗ NCT02802111 ↗ NCT02799784 ↗ NCT02797275 ↗ NCT00385359 ↗ NCT00114478 ↗ NCT05363670 ↗ NCT06271408 ↗ NCT00635505 ↗ NCT02966184 ↗ NCT01885936 ↗ NCT01791972 ↗ NCT02969408 ↗ NCT00393367 ↗ NCT00319488 ↗ NCT02483975 ↗ NCT00005110 ↗ NCT01951378 ↗ NCT01747629 ↗ NCT02654145 ↗
Known as	Albuterol eMDPI	“Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:” NCT03890666 ↗
Known as	Albuterol eMDPI DS	“Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:” NCT03890666 ↗
Known as	Albuterol HCl	“Albuterol HCl Inhalation Solution” NCT00685126 ↗
Known as	albuterol MDPI	“OBJECTIVE: To evaluate albuterol MDPI efficacy and safety in patients with exercise-induced bronchoconstriction (EIB).” PMID 26475054 ↗ Sep 2015
Known as	Albuterol Spiromax	“Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate.” NCT01791972 ↗ 4 “Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose” NCT01844401 ↗ “Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)” NCT01857323 ↗ “Albuterol Spiromax® delivers 90 mcg albuterol per inhalation.” NCT01058863 ↗ NCT01899144 ↗
Known as	albuterol Sulfate	“Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA) inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to...” NCT02182674 ↗ 42 “The objective of this study was to investigate the bioequivalence of Mylan's albuterol sulfate extended-release 8 mg tablets to Pliva's VoSpire™ ER 8 mg tablets following a...” NCT00649779 ↗ “This is a Phase 3B, 12-week, multicenter, open-label study to evaluate the relationship between albuterol sulfate (ABS) eMDPI and clinical asthma exacerbation (CAE) in adult...” NCT02969408 ↗ “Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants...” NCT00550550 ↗ “Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.” NCT00562159 ↗ “Measurements were made at baseline and at 30, 60 and 90 min following the administration of a nebulized β(2)-agonist (albuterol sulfate, 2.5 mg diluted in 3 ml normal saline).” PMID 21889619 ↗ Aug 2011 “Co-suspension Delivery™ Technology has been developed for the administration of albuterol sulfate pressurised inhalation suspension via metered-dose inhaler (AS MDI, PT007).” PMID 34089147 ↗ Jun 2021 “Co-suspension Delivery™ Technology has been developed for the administration of albuterol sulfate pressurised inhalation suspension via metered-dose inhaler (AS MDI, PT007).” PMID 34089147 ↗ Jun 2021 “The drug product albuterol sulfate DPI, TBS-7, is a single dose inhalation product of albuterol sulfate containing 240 ug albuterol sulphate (200 ug of albuterol)” NCT01252758 ↗ “Participants will receive Albuterol Sulfate MDI 90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.” NCT05505734 ↗ “Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 μg per puff. Two puffs to administer 160/180 μg dose.” NCT04848662 ↗ “Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 3 component devices:” NCT05241288 ↗ “Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:” NCT03890666 ↗ “fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination” NCT06290102 ↗ “Albuterol sulfate, USP, solution for inhalation will be diluted as follows:” NCT00434993 ↗ “3. albuterol sulfate as needed for relief of acute respiratory symptoms” NCT03952286 ↗ “Albuterol sulfate, a β2-adrenergic agonist, reduces IL-12 expression” PMID 20837847 ↗ Sep 2010 “PROAIR® HFA (Albuterol Sulfate) Inhalation Aerosol, eq 90 mcg Base” NCT03549897 ↗ “PROAIR™ HFA (Albuterol Sulfate) Breath Actuated Inhalation Aerosol” NCT00308685 ↗ “Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution” NCT06271408 ↗ “Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution” NCT06946264 ↗ “Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation)” NCT06154304 ↗ “Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg” NCT00462540 ↗ “Albuterol Sulfate metered dose inhaler [AS MDI] - PT007)” NCT06644924 ↗ “Treatment C (Albuterol Sulfate metered dose inhaler)” NCT03772223 ↗ “fluticasone propionate/albuterol sulfate combination” NCT06664619 ↗ “Albuterol Sulfate Extended-Release Tablets 8 mg” NCT00649987 ↗ “Albuterol sulfate metered-dose inhaler (AS MDI)” NCT06307665 ↗ “Albuterol sulfate inhalation aerosol” NCT03769090 ↗ “Albuterol Sulfate (Provenetil-HFA)” NCT00634829 ↗ “Salbutamol(Albuterol) Sulfate” NCT03098680 ↗ “Drug: albuterol Sulfate” NCT00667797 ↗ “Drug: Albuterol Sulfate” NCT00665600 ↗ NCT04912596 ↗ NCT06471257 ↗ NCT03091504 ↗ NCT00565591 ↗ NCT03847896 ↗ NCT00144846 ↗ NCT02566252 ↗ NCT00394329 ↗ NCT07426458 ↗ NCT03528577 ↗
Known as	Albuterol Sulfate Acu-30 DPI	“A Stepwise, Rising Dose Study of Male Subjects With Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI Compared With...” NCT00565591 ↗
Known as	Albuterol Sulfate HFA	“Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation” NCT04912596 ↗
Known as	albuterol sulphate	“The drug product albuterol sulfate DPI, TBS-7, is a single dose inhalation product of albuterol sulfate containing 240 ug albuterol sulphate (200 ug of albuterol)” NCT01252758 ↗ 1 “Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours” NCT01987219 ↗
Known as	Albuterol-HFA	“This 12-week clinical study evaluates the safety and efficacy of Albuterol Sulfate HFA Inhalation Aerosol (Albuterol-HFA, or: A004), Armstrong's proposed HFA formulation of...” NCT00635505 ↗
Known as	Albuterol/Salbutamol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02478398 ↗ 1 NCT00070707 ↗
Known as	Armstrong Albuterol HFA	“albuterol (Armstrong Albuterol HFA)” NCT00634829 ↗
Known as	AS MDI	“Co-suspension Delivery™ Technology has been developed for the administration of albuterol sulfate pressurised inhalation suspension via metered-dose inhaler (AS MDI, PT007).” PMID 34089147 ↗ Jun 2021 2 “Albuterol Sulfate metered dose inhaler [AS MDI] - PT007)” NCT06644924 ↗ “Albuterol sulfate AS MDI (PT007)” NCT03847896 ↗
Known as	etinoline	“At the acute stage of asthma : etinoline,twice a day for 7 days” NCT02341573 ↗
Known as	Meptin swinghaler	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01095016 ↗
Known as	Pro-Air	“Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment...” NCT01772368 ↗
Known as	PROAIR HFA	“Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation” NCT04912596 ↗ 6 “ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose” NCT01844401 ↗ “PROAIR® HFA (Albuterol Sulfate) Inhalation Aerosol, eq 90 mcg Base” NCT03549897 ↗ “PROAIR™ HFA (Albuterol Sulfate) Breath Actuated Inhalation Aerosol” NCT00308685 ↗ “ProAir® HFA delivers 90 mcg of albuterol per inhalation.” NCT01058863 ↗ “PROAIR® HFA (albuterol sulfate) Inhalation Aerosol” NCT03528577 ↗ NCT01899144 ↗
Known as	ProAir RespiClick	“ProAir® RespiClick, Albuterol multi-dose dry powder inhaler (MDPI)” NCT01857323 ↗
Known as	ProAir RespiClick, Albuterol multi-dose dry powder inhaler (MDPI)	“ProAir® RespiClick, Albuterol multi-dose dry powder inhaler (MDPI)” NCT01218009 ↗ 1 “ProAir® RespiClick, Albuterol multi-dose dry powder inhaler (MDPI)” NCT01058863 ↗
Known as	Proventil	“The effects of albuterol delivered via AS MDI and Proventil on bronchodilation were equivalent, supporting the selection of AS MDI 180 µg to be taken into Phase III clinical...” PMID 34089147 ↗ Jun 2021 2 “(Proventil ®)” NCT01987219 ↗ NCT02271334 ↗
Known as	Proventil HFA	“A recent study demonstrated that patients with mild asthma and the Arg/Arg variant at the 16th amino acid position have improved lung function and asthma control when albuterol...” NCT00521222 ↗ 2 “A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active control, Proventil-HFA (Albuterol Metered Dose Inhaler (MDI))” NCT01189396 ↗ “Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study.” NCT00577655 ↗
Known as	PT007	“Co-suspension Delivery™ Technology has been developed for the administration of albuterol sulfate pressurised inhalation suspension via metered-dose inhaler (AS MDI, PT007).” PMID 34089147 ↗ Jun 2021 2 “Albuterol Sulfate metered dose inhaler [AS MDI] - PT007)” NCT06644924 ↗ “Albuterol sulfate AS MDI (PT007)” NCT03847896 ↗
Known as	Racemic albuterol	“Racemic albuterol (0.63, 1.25 mg or 2.5 mg); the first three doses will be delivered every 20 minutes for the first hour.” NCT00685126 ↗
Known as	racemic salbutamol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00830882 ↗ 1 NCT00831376 ↗
Known as	S-albuterol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00320034 ↗
Known as	SALB	“Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL).” NCT02782052 ↗
Known as	SalbG	“(Salbutamol Generic, SalbG)” NCT05884970 ↗
Known as	SalbR	“reference product (Ventolin, Salbutamol Reference, SalbR)” NCT05884970 ↗
Known as	Salbultamol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00990847 ↗
Known as	Salbutamol Generic	“(Salbutamol Generic, SalbG)” NCT05884970 ↗
Known as	Salbutamol Reference	“reference product (Ventolin, Salbutamol Reference, SalbR)” NCT05884970 ↗
Known as	Salbutamol Sandoz	“"100 mcg Salbutamol Sandoz" and "300 mcg Salbutamol Sandoz"” NCT05884970 ↗
Known as	Salbutamol Sulfate	“Each participant received aerosolized salbutamol sulfate consisting of 1 mL Farcolin® solution containing 6050 µg salbutamol sulfate diluted with 2 mL normal saline placed...” NCT07633223 ↗ 8 “Nebulized bronchodilator drugs will be Salbutamol Sulfate (aerolin nebulis) and ipratropium bromide (atrovent) diluted in a saline solution (saline 0.9%) in 3 ml.” NCT03271905 ↗ “Nebulization of ipratropium bromide/salbutamol sulfate (500 µg/2.5 mg) before the administration of the Glittre ADL-test” NCT03071731 ↗ “Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate.” NCT04584034 ↗ “Fluticasone Propionate/Salbutamol Sulfate. Oral inhalation powder.” NCT06052267 ↗ “Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff” NCT02182713 ↗ “Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet” NCT05099107 ↗ “Ventolin® MDI * Ingredient: Salbutamol sulfate” NCT01076322 ↗ NCT02182700 ↗
Known as	salbutamol sulphate	“As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens” NCT03842839 ↗ 5 “120 mcg salbutamol sulphate (equivalent to 100 mcg of the base)” NCT02182713 ↗ “Salbutamol sulphate (2.5 mg) + ipratropium bromide (0.5 mg)” NCT06825013 ↗ “VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)” NCT02405598 ↗ “Drug: Salbutamol sulphate” NCT01521572 ↗ NCT02182856 ↗
Known as	Salbutamol Sulphate BP	“Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)” NCT03333395 ↗
Known as	Salbutamol Sulphate Inhalation Aerosol (Ventolin)	“Salbutamol Sulphate Inhalation Aerosol (Ventolin®)” NCT03169504 ↗
Known as	Salbutamol Ventolin GSK	“"100 mcg Salbutamol Ventolin GSK" and "300 mcg Salbutamol Ventolin GSK"” NCT05884970 ↗
Known as	TBS-7	“The drug product albuterol sulfate DPI, TBS-7, is a single dose inhalation product of albuterol sulfate containing 240 ug albuterol sulphate (200 ug of albuterol)” NCT01252758 ↗
Known as	Ventilastin	“Salbutamol inhaler (200 µg per puff; a short acting β2-agonist; Ventilastin®).” NCT00633919 ↗
Known as	Ventolin	“cough medicine (such as codeine), bronchodilators (such as ventolin), expectorants (such as fluimucil) and so on are used to treat cough, shortness of breath, or other...” NCT06095258 ↗ 22 “Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulized salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland)...” NCT05527704 ↗ “Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)” NCT03333395 ↗ “The bronchodilator used in the study is the Salbutamol as Ventolin ® (GSK) suspension for inhalation as an aerosol at a dose of 100μg per puff.” NCT01470755 ↗ “Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate.” NCT04584034 ↗ “Nebulized salbutamol (Ventolin respiratory solution) 2.5 mg stat and once only with standard care” NCT02160548 ↗ “Salbutamol will be used to Group A patients: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose.” NCT03745261 ↗ “Ipratropium Bromide (Atrovent) & Albuterol (Ventolin) as Standard of Care” NCT04655170 ↗ “The drugs used by the children were zespira and ventolin.” NCT05930847 ↗ “Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp)” NCT00628758 ↗ “Tiotropium (Spiriva) + Salbutamol (Ventolin)” NCT00981851 ↗ “VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)” NCT02405598 ↗ “100 μg of albuterol (Ventolin®)” NCT01112241 ↗ “Salbutamol (Ventolin®)” NCT07591558 ↗ “Salbutamol (Ventolin®)” NCT06918418 ↗ “Salbutamol (Ventolin®)” NCT07378605 ↗ “Salbutamol (Ventolin®)” NCT06921291 ↗ “Ventolin” NCT01997463 ↗ NCT03468790 ↗ NCT00876135 ↗ NCT04159519 ↗ NCT04606394 ↗ NCT04929626 ↗
Known as	Ventolin (salbutamol)	“Ventolin (salbutamol)” NCT00876135 ↗ 1 “VENTOLIN (salbutamol)” NCT03924635 ↗
Known as	ventolin 2.5 Nebules 2.5mg/2.5 ml	“2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator)” NCT02159196 ↗
Known as	Ventolin MDI	“Ventolin® MDI * Ingredient: Salbutamol sulfate” NCT01076322 ↗
Known as	Ventoline	“The purpose of the project is to investigate whether the use of a WADA approved dose of salbutamol (albuterol/Ventoline) has a performance-enhancing effect on sprint...” NCT04402658 ↗ 1 NCT02103374 ↗
Known as	VentolinTM	“Salbutamol (VentolinTM) is a short acting beta agonist (SABA) which is used to treat wheezing, dyspnea and breathing difficulties caused by asthma and COPD.” NCT00911651 ↗
Known as	Volmax	“Volmax tb 4 mg/8 mg” NCT00628758 ↗
Known as	VoSpire ER	“The objective of this study was to investigate the bioequivalence of Mylan's albuterol sulfate extended-release 8 mg tablets to Pliva's VoSpire™ ER 8 mg tablets following a...” NCT00649779 ↗
Action	Inhibit	“reduces IL-12 expression” PMID 20837847 ↗ Sep 2010
Modality	Other / unclassified	“aerosolized β₂-agonist” PMID 21562125 ↗ Sep 2011
Route	Inhaled	“inhaled albuterol” NCT00000577 ↗